#Israel #Immunotherapy #Compugen #Holon #UnigenX™

Compugen's Presentation at PEGS Europe 2026

Compugen Ltd., a pioneer in the field of cancer immunotherapy, will be featured at the prestigious 18th Annual Protein and Antibody Engineering Summit (PEGS) Europe taking place from November 16 to 19, 2026, in Lisbon, Portugal. The company, listed on both the Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN, has established itself as a clinical-stage leader in computational target discovery powered by artificial intelligence.

At this summit, Compugen will provide an oral presentation highlighting its latest innovation—the UnigenX™ platform. This advancement represents an expansion of the company’s existing computational discovery efforts, now targeting immune activation modalities. Specifically, UnigenX™ aims to uncover novel tumor-associated antigen targets and combinations for more selective targeting of tumor cells. The focus will be on advancing multispecific antibodies and combination therapy strategies.

Presentation Details

The presentation titled "UnigenX™ AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation" will be delivered by Dr. Roy Granit, the Head of Computational Discovery at Compugen. It is scheduled for Wednesday, November 18, 2026, at 18:30 GMT.

About Compugen

Compugen is dedicated to the discovery and development of innovative therapeutic solutions. Their flagship platform, Unigen™, leverages AI to identify novel drug targets, facilitating the development of new cancer immunotherapies. Compugen's current pipeline includes several promising candidates:

• - COM701: This potential first-in-class anti-PVRIG antibody is currently under evaluation in a Phase 2 trial as a maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer. This trial aims at establishing the efficacy of COM701 in a blinded randomized context, known as the MAIA-ovarian trial.

• - Rilvegostomig: This bispecific antibody targets both PD-1 and TIGIT and is being further developed under a collaboration agreement with AstraZeneca, which is executing multiple Phase 1, 2, and 3 trials to assess its efficacy.

• - GS-0321: Previously known as COM503, GS-0321 is designed to inhibit the interaction between IL-18 binding protein and IL-18. This antibody is licensed to Gilead and is currently being tested in a Phase 1 clinical trial.

In addition to these clinical-stage products, Compugen maintains an early-stage pipeline that explores various research programs aimed at enhancing anti-cancer immunity. The company's commitment to innovating in the oncology space is evident in its systematic approach to identifying and validating therapeutic targets.

As the PEGS Europe Summit approaches, anticipation builds around Compugen’s potential contributions to the field of cancer treatment. By presenting the UnigenX™ platform, Compugen aims to not only highlight its computational capabilities but also to network with other industry leaders and foster collaborations that could drive the development of next-generation cancer therapies.

For further inquiries, interested parties can reach out to Lindsey Trickett at [email protected] or through her direct line at +1 415 373 0892. Compugen continues to evolve as a leader in immuno-oncology, reaffirming its mission to address the challenges of cancer treatment using cutting-edge technology and innovative research.